Logo
x

Search

Subscribe Now

Cross-Licensing Agreement

CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights to Facilitate Cell Therapy Programs in Oncology

CRISPR Therapeutics and KSQ Therapeutics Cross Licenses their IP Rights to Facilitate Cell Therapy Programs in Oncology

  • October 15, 2019
Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

  • April 4, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.